Unilife (NASDAQ:UNIS) announced a strategic collaboration with Amgen (NASDAQ:AMGN) on Monday.
The collaboration includes licensing, investment, development and supply agreements related to the use of Unilife's portfolio of pre-filled, customisable wearable injectors for medicines to enhance the patient experience.
Under the terms of the collaboration, Unilife has granted Amgen exclusive rights to Unilife's wearable injectors within select drug classes for use with certain Amgen assets, while preserving rights previously granted to other Unilife customers.
Unilife has also granted Amgen non-exclusive rights to all proprietary Unilife delivery systems within the therapeutic areas of oncology, inflammation, bone health, nephrology, cardiovascular and neuroscience.
Although close to session lows, Unilife shares were still 14.3% higher at $1.12, while Amgen's shares were down. 1.1% at $148.45.